Cargando…

Extensive cardiac FDG uptake in a patient with AL amyloidosis

Cardiac AL amyloidosis is a medical emergency causing rapid deterioration of cardiac function; however, it remains to be a diagnostic challenge especially when presenting with unusual symptoms and clinical findings. We present case of a 44-year-old patient with typical angina, persistently elevated...

Descripción completa

Detalles Bibliográficos
Autores principales: Hatipoglu, Suzan, Wechalekar, Ashutosh D., Wechalekar, Kshama
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022573/
https://www.ncbi.nlm.nih.gov/pubmed/36930456
http://dx.doi.org/10.1007/s12350-023-03243-1
_version_ 1784908758462234624
author Hatipoglu, Suzan
Wechalekar, Ashutosh D.
Wechalekar, Kshama
author_facet Hatipoglu, Suzan
Wechalekar, Ashutosh D.
Wechalekar, Kshama
author_sort Hatipoglu, Suzan
collection PubMed
description Cardiac AL amyloidosis is a medical emergency causing rapid deterioration of cardiac function; however, it remains to be a diagnostic challenge especially when presenting with unusual symptoms and clinical findings. We present case of a 44-year-old patient with typical angina, persistently elevated troponin and normal epicardial coronary arteries. He was initially treated for myocarditis due to chest pain with troponin rise. However, CMR finding of subendocardial enhancement, increased native T1 values as well as extensive diffuse FDG uptake on PET-CT also suggested inflammatory cardiac conditions. Rapid decline in LV function and clinical deterioration led to further investigations including serum free light chains and bone marrow biopsy which confirmed systemic AL amyloidosis. Although the pathophysiology of unusual FDG PET-CT findings remains unknown, marked myocardial FDG uptake might have been caused by various features that were associated with AL amyloidosis including myocardial cell toxicity/inflammation or microvascular dysfunction. Awareness of these features specific to AL amyloidosis among physicians and description of associated cardiac FDG uptake findings has a potential to aid early diagnosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12350-023-03243-1.
format Online
Article
Text
id pubmed-10022573
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-100225732023-03-17 Extensive cardiac FDG uptake in a patient with AL amyloidosis Hatipoglu, Suzan Wechalekar, Ashutosh D. Wechalekar, Kshama J Nucl Cardiol Case Presentation Corner Cardiac AL amyloidosis is a medical emergency causing rapid deterioration of cardiac function; however, it remains to be a diagnostic challenge especially when presenting with unusual symptoms and clinical findings. We present case of a 44-year-old patient with typical angina, persistently elevated troponin and normal epicardial coronary arteries. He was initially treated for myocarditis due to chest pain with troponin rise. However, CMR finding of subendocardial enhancement, increased native T1 values as well as extensive diffuse FDG uptake on PET-CT also suggested inflammatory cardiac conditions. Rapid decline in LV function and clinical deterioration led to further investigations including serum free light chains and bone marrow biopsy which confirmed systemic AL amyloidosis. Although the pathophysiology of unusual FDG PET-CT findings remains unknown, marked myocardial FDG uptake might have been caused by various features that were associated with AL amyloidosis including myocardial cell toxicity/inflammation or microvascular dysfunction. Awareness of these features specific to AL amyloidosis among physicians and description of associated cardiac FDG uptake findings has a potential to aid early diagnosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12350-023-03243-1. Springer International Publishing 2023-03-17 /pmc/articles/PMC10022573/ /pubmed/36930456 http://dx.doi.org/10.1007/s12350-023-03243-1 Text en © The Author(s) under exclusive licence to American Society of Nuclear Cardiology 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Case Presentation Corner
Hatipoglu, Suzan
Wechalekar, Ashutosh D.
Wechalekar, Kshama
Extensive cardiac FDG uptake in a patient with AL amyloidosis
title Extensive cardiac FDG uptake in a patient with AL amyloidosis
title_full Extensive cardiac FDG uptake in a patient with AL amyloidosis
title_fullStr Extensive cardiac FDG uptake in a patient with AL amyloidosis
title_full_unstemmed Extensive cardiac FDG uptake in a patient with AL amyloidosis
title_short Extensive cardiac FDG uptake in a patient with AL amyloidosis
title_sort extensive cardiac fdg uptake in a patient with al amyloidosis
topic Case Presentation Corner
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022573/
https://www.ncbi.nlm.nih.gov/pubmed/36930456
http://dx.doi.org/10.1007/s12350-023-03243-1
work_keys_str_mv AT hatipoglusuzan extensivecardiacfdguptakeinapatientwithalamyloidosis
AT wechalekarashutoshd extensivecardiacfdguptakeinapatientwithalamyloidosis
AT wechalekarkshama extensivecardiacfdguptakeinapatientwithalamyloidosis